NCLT clears Sequent Scientific–Viyash Life Sciences merger worth ₹8,000 crore

Carlyle's portfolio companies, Sequent Scientific and Viyash Life Sciences, have received National Company Law Tribunal approval for their planned Rs 8,000 crore merger. This strategic combination aims to leverage back-end synergies between Sequent's animal health business and Viyash's human health drug manufacturing operations. Hari Babu Bodepudi, Viyash's founder, will lead the combined entity as CEO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i0Y3AqC
via IFTTT